Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ARVN

Arvinas (ARVN)

Arvinas Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARVN
DateTimeSourceHeadlineSymbolCompany
06/24/20244:37PMGlobeNewswire Inc.Arvinas Appoints Andrew Saik as Chief Financial Officer and TreasurerNASDAQ:ARVNArvinas Inc
06/21/20247:00AMGlobeNewswire Inc.Arvinas Announces Presentations for Two of its PROTACĀ® Investigational Programs Targeting BCL6 and LRRK2NASDAQ:ARVNArvinas Inc
06/18/20245:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
06/18/20245:51PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
06/18/20244:55PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
06/17/20247:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
06/17/20247:00AMGlobeNewswire Inc.Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific OfficerNASDAQ:ARVNArvinas Inc
06/03/20244:30PMGlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
05/31/20245:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
05/30/20244:52PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/23/20249:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
05/23/20245:00PMGlobeNewswire Inc.Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual CongressNASDAQ:ARVNArvinas Inc
05/16/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/16/20246:00AMGlobeNewswire Inc.Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)NASDAQ:ARVNArvinas Inc
05/09/20244:42PMGlobeNewswire Inc.Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNASDAQ:ARVNArvinas Inc
05/07/20244:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARVNArvinas Inc
05/07/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/07/20247:00AMGlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
05/02/20247:00AMGlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
04/24/20244:30PMGlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
04/11/20247:00AMGlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTACĀ® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
03/18/20244:40PMGlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
03/04/20247:00AMGlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
02/27/20246:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20246:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20246:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20246:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20244:46PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
02/27/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
02/27/20247:00AMGlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
 Showing the most relevant articles for your search:NASDAQ:ARVN